Boehringer and Surrozen Seek Retinal Therapies Along the Wnt Pathway

Surrozen Inc announced Thursday it has partnered with Boehringer Ingelheim to research and develop a therapeutic for the treatment of retinal diseases.

The partnership, valued at nearly $600 million, centers on Surrozen's developmental compound SZN-413, a bi-specific antibody targeting Fzd4-mediated and LRP5 Wnt signaling.